Last $11.41 USD
Change Today -0.15 / -1.30%
Volume 556.6K
VOLC On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3721 Valley Centre Drive

Suite 500

San Diego, CA 92130

United States

Phone: 800-228-4728

Fax: 858-720-0325

Volcano Corporation designs, develops, manufactures and commercializes precision guided therapy tools, including intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products. The company, through its wholly owned subsidiary, Axsun Technologies, Inc. (Axsun), develops and manufactures optical monitors for the telecommunications industry, laser and non-laser light sources, optical engines used in medical optical coherence topography (OCT), imaging systems and advanced photonic components and sub-systems used in spectroscopy and other industrial applications. The company owns Crux Biomedical, Inc., or Crux, a private company developing various products designed to capture emboli (blood vessel package) and other debris through the vasculature. These include the Crux VCF System, featuring the Crux IVC filter, a retrievable filter intended to prevent recurrent pulmonary embolism (blockage of main artery of the lung). The company launched the Crux VCF System in 2013 and also received 510(k) clearance for its Crux Snare Retrieval Set in January 2014. During 2013, the company acquired the Pioneer Plus Re-Entry Catheter designed to enable the crossing of sub-total, total and chronic total occlusions within the peripheral vasculature. The company’s IVUS technology is used to direct the guidewire past stenotic lesions prior to additional interventions. The company is developing high resolution focal acoustic computed tomography (FACT), catheters, co-registration with IVUS and an IVUS-guided Crux VCF system featuring its inferior vena cava, or IVC, filter. In addition, the company has various products in its emerging business segment, including IVUS-guided therapies, such as its Pioneer Plus Re-entry catheter, its Crux IVC filter, Axsun medical and ophthalmology products, SyncVision (co-registration with IVUS) and iFR. Segments The company’s segments include Medical and Industrial. The Medical segment engages in the sale of the company’s multi-modality and FFR consoles and its IVUS and FFR single-use disposables. The Industrial segment engages in the sale of micro-optical spectrometers and optical channel monitors by Axsun to telecommunication and industrial companies. Strategy The company’s long-term growth strategy incorporates expansion of its existing businesses, commercialization of new products and markets and licensing or acquiring new technologies. Factors driving the company’s strategy include accelerating the trend toward less invasive procedures; enhancing the outcomes of PCI and endovascular procedures; providing documentation for necessity of procedures; decreasing the number of interventional devices used per procedure and optimizing their usage; improving ease of use of IVUS and FFR technologies to drive market adoption; improving the diagnosis of cardiovascular disease; and enabling new procedures to treat coronary artery, and peripheral vascular disease. The key elements of the company’s strategy include growing existing IVUS and FFR markets globally; increasing market share in existing IVUS and FFR markets; expanding its existing technologies to serve new markets; and enhancing product capabilities and introduce new products through collaborations or acquisitions. Products The company’s products consist of consoles that are marketed as units or as units that can be integrated into various hospital-based interventional surgical suites called catheterization laboratories, or cath labs. The company has developed customized cath lab versions of these consoles and is developing additional functionality options as part of its cath lab integration initiative. The company’s consoles have been designed to serve as a multi-modality platform for its phased array and rotational IVUS catheters, FFR pressure and flow wires and image-guided therapy catheters, such as the Pioneer Plus reentry device acquired from Medtronic, Inc., or Medtronic, on August 30, 2013. The company’s multi-modality consoles are marketed as stand-alone units or units that can be integrated into cath labs. The company offers consoles that combine IVUS and FFR technology, which are designed to allow the

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VOLC:US $11.41 USD -0.15

VOLC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $25.35 USD -0.08
AtriCure Inc $14.98 USD -0.38
Cardiovascular Systems Inc $26.86 USD -0.13
Spectranetics Corp/The $28.04 USD +0.03
Vascular Solutions Inc $23.46 USD -0.22
View Industry Companies
 

Industry Analysis

VOLC

Industry Average

Valuation VOLC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLCANO CORP, please visit www.volcanocorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.